FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376106129> ?p ?o ?g. }

• W4376106129 endingPage "13" @default.
• W4376106129 startingPage "12" @default.
• W4376106129 abstract "Background: Until the recent introduction of daratumumab (Dara), bortezomib-melphalan-prednisone (VMP) and lenalidomide-dexamethasone (Rd) have been standards of care for transplant-ineligible (NTE) newly diagnosed multiple myeloma (NDMM) patients (pts) in the frontline setting. Nonetheless, no prospective randomized trial has directly compared VMP with Rd, and only few data on real-life experiences in older NTE pts are available. Methods: In this multicenter randomized phase IV trial (NCT03829371; funded by the Italian Medicines Agency AIFA - Independent Research), real-life NDMM pts ineligible for transplant due to comorbidities or age ≥65 years were randomized 1:1 to VMP (nine 42-day [dd] cycles [cc], V: 1.3 mg/m2 dd 1,4,8,11,22,25,29,32 cc 1-4 and dd 1,8,22,29 cc 5-9; M: 9 mg/m2 dd 1-4; P: 60 mg/m2 dd 1-4) vs continuous Rd (28-day cc, R: 25 mg dd 1-21; d: 40 mg dd 1,8,15,22), according to standard practice. Upon written informed consent, pts were enrolled regardless of comorbidities, performance status, baseline laboratory values, or renal function. Stratification was performed according to the International Myeloma Working Group frailty score and to cytogenetic risk by fluorescence in situ hybridization [high risk with del(17p), t(14;16), or t(4;14)]. Progression-free survival (PFS) in the intention-to-treat (ITT) population was the primary endpoint. Overall survival (OS), response rates, and safety were key secondary endpoints. Results: The data cut-off was July 4, 2022: 231 pts were randomly assigned to VMP (n=114) or Rd (n=117). Baseline characteristics were balanced in VMP vs Rd: median age 77 (IQR 73-80) and 76 years (IQR 73-79); frail pts 49% vs 50%; pts with high-risk cytogenetics 17% vs 19%. After a median follow-up of 19 months, median PFS in the ITT population was 29.6 vs 26.2 months with VMP vs Rd (hazard ratio [HR] 0.82, 95% CI 0.51-1.31, P=0.41; Fig. 1A). HR was 0.21 (95% CI 0.04-0.99) in pts with high-risk cytogenetics vs 1.24 (95% CI 0.70-2.18) in standard-risk pts (interaction P=0.036). No differences in terms of age or frailty status were observed. In the ITT population, 2-year OS was 89% with VMP vs 75% with Rd (HR 0.53, 95% CI 0.26-1.07, P=0.08; Fig. 1B). No safety concerns were reported. Thrombocytopenia (15%) and neuropathy (7%) were the most frequent grade 3-4 adverse events with VMP; neutropenia (23%), infections (12%), and dermatologic toxicities (9%) with Rd. At least 1 dose reduction (any drug) was reported in 66% of pts in the VMP and 59% in the Rd arms, including 35% of pts in the VMP arm switching to once-weekly V before cc 5. Conclusion: Overall, the advantage of Rd over VMP was lower than anticipated in this older real-life NTE NDMM population with 50% of frail patients. However, a strong effect modification by cytogenetic risk was found, with high-risk pts benefiting more from VMP vs Rd in terms of PFS (HR 0.21). Safety data were consistent with those previously reported. Of note, only 1/3 of real-life pts were able to receive full-dose VMP or Rd. Despite the limited follow-up, the poor outcomes in pts failing R-based treatment could explain the different OS rates in the two arms. As of July 2022, pts have been randomized to Dara-VMP vs Dara-Rd. With longer follow-up, an analysis of the addition of Dara will further improve decision-making." @default.
• W4376106129 created "2023-05-12" @default.
• W4376106129 creator A5008923543 @default.
• W4376106129 creator A5011678278 @default.
• W4376106129 creator A5015195779 @default.
• W4376106129 creator A5018139001 @default.
• W4376106129 creator A5023517351 @default.
• W4376106129 creator A5024104400 @default.
• W4376106129 creator A5025049786 @default.
• W4376106129 creator A5025476428 @default.
• W4376106129 creator A5026430732 @default.
• W4376106129 creator A5028704362 @default.
• W4376106129 creator A5037700899 @default.
• W4376106129 creator A5038714035 @default.
• W4376106129 creator A5040064061 @default.
• W4376106129 creator A5044306304 @default.
• W4376106129 creator A5044763057 @default.
• W4376106129 creator A5046704362 @default.
• W4376106129 creator A5047217205 @default.
• W4376106129 creator A5057333997 @default.
• W4376106129 creator A5060531634 @default.
• W4376106129 creator A5063033515 @default.
• W4376106129 creator A5064478569 @default.
• W4376106129 creator A5066814162 @default.
• W4376106129 creator A5067110512 @default.
• W4376106129 creator A5071926851 @default.
• W4376106129 creator A5072657141 @default.
• W4376106129 creator A5076770010 @default.
• W4376106129 creator A5083314734 @default.
• W4376106129 creator A5083644983 @default.
• W4376106129 creator A5088706955 @default.
• W4376106129 date "2023-05-01" @default.
• W4376106129 modified "2023-09-27" @default.
• W4376106129 title "P07 BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) IN REAL-LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL" @default.
• W4376106129 doi "https://doi.org/10.1097/01.hs9.0000936156.32733.12" @default.
• W4376106129 hasPublicationYear "2023" @default.
• W4376106129 type Work @default.
• W4376106129 citedByCount "0" @default.
• W4376106129 crossrefType "journal-article" @default.
• W4376106129 hasAuthorship W4376106129A5008923543 @default.
• W4376106129 hasAuthorship W4376106129A5011678278 @default.
• W4376106129 hasAuthorship W4376106129A5015195779 @default.
• W4376106129 hasAuthorship W4376106129A5018139001 @default.
• W4376106129 hasAuthorship W4376106129A5023517351 @default.
• W4376106129 hasAuthorship W4376106129A5024104400 @default.
• W4376106129 hasAuthorship W4376106129A5025049786 @default.
• W4376106129 hasAuthorship W4376106129A5025476428 @default.
• W4376106129 hasAuthorship W4376106129A5026430732 @default.
• W4376106129 hasAuthorship W4376106129A5028704362 @default.
• W4376106129 hasAuthorship W4376106129A5037700899 @default.
• W4376106129 hasAuthorship W4376106129A5038714035 @default.
• W4376106129 hasAuthorship W4376106129A5040064061 @default.
• W4376106129 hasAuthorship W4376106129A5044306304 @default.
• W4376106129 hasAuthorship W4376106129A5044763057 @default.
• W4376106129 hasAuthorship W4376106129A5046704362 @default.
• W4376106129 hasAuthorship W4376106129A5047217205 @default.
• W4376106129 hasAuthorship W4376106129A5057333997 @default.
• W4376106129 hasAuthorship W4376106129A5060531634 @default.
• W4376106129 hasAuthorship W4376106129A5063033515 @default.
• W4376106129 hasAuthorship W4376106129A5064478569 @default.
• W4376106129 hasAuthorship W4376106129A5066814162 @default.
• W4376106129 hasAuthorship W4376106129A5067110512 @default.
• W4376106129 hasAuthorship W4376106129A5071926851 @default.
• W4376106129 hasAuthorship W4376106129A5072657141 @default.
• W4376106129 hasAuthorship W4376106129A5076770010 @default.
• W4376106129 hasAuthorship W4376106129A5083314734 @default.
• W4376106129 hasAuthorship W4376106129A5083644983 @default.
• W4376106129 hasAuthorship W4376106129A5088706955 @default.
• W4376106129 hasBestOaLocation W43761061291 @default.
• W4376106129 hasConcept C126322002 @default.
• W4376106129 hasConcept C141071460 @default.
• W4376106129 hasConcept C143998085 @default.
• W4376106129 hasConcept C168563851 @default.
• W4376106129 hasConcept C203092338 @default.
• W4376106129 hasConcept C2776063141 @default.
• W4376106129 hasConcept C2776364478 @default.
• W4376106129 hasConcept C2778684742 @default.
• W4376106129 hasConcept C2781119759 @default.
• W4376106129 hasConcept C2908647359 @default.
• W4376106129 hasConcept C71924100 @default.
• W4376106129 hasConcept C99454951 @default.
• W4376106129 hasConceptScore W4376106129C126322002 @default.
• W4376106129 hasConceptScore W4376106129C141071460 @default.
• W4376106129 hasConceptScore W4376106129C143998085 @default.
• W4376106129 hasConceptScore W4376106129C168563851 @default.
• W4376106129 hasConceptScore W4376106129C203092338 @default.
• W4376106129 hasConceptScore W4376106129C2776063141 @default.
• W4376106129 hasConceptScore W4376106129C2776364478 @default.
• W4376106129 hasConceptScore W4376106129C2778684742 @default.
• W4376106129 hasConceptScore W4376106129C2781119759 @default.
• W4376106129 hasConceptScore W4376106129C2908647359 @default.
• W4376106129 hasConceptScore W4376106129C71924100 @default.
• W4376106129 hasConceptScore W4376106129C99454951 @default.
• W4376106129 hasIssue "S2" @default.
• W4376106129 hasLocation W43761061291 @default.
• W4376106129 hasLocation W43761061292 @default.
• W4376106129 hasLocation W43761061293 @default.
• W4376106129 hasOpenAccess W4376106129 @default.

• next